On Jan 5, 2022, Hologic the addition of the Aptimaﾮ SARS-CoV-2 assay to its Global Access Initiative, a program designed to expand access to critical diagnostic testing in resource-limited countries.

As a global leader in diagnostics, Hologic launched the GAI at the 2018 International AIDS Conference with a breakthrough all-inclusive pricing structure with no upfront cost or capital expenditure. Qualified products included molecular assays for human immunodeficiency virus-1 (HIV-1), hepatitis B and C (HBV and HCV) and human papillomavirus (HPV), as well as the ThinPrepﾮ Pap test for cervical cancer screening.